Your browser doesn't support javascript.
loading
Clinical Efficacy and Effects on Serum Inflammatory Factors of Carbocisteine Combined with Budesonide in the Treatment of Asthma / 中国药师
China Pharmacist ; (12): 106-108, 2017.
Article Dans Chinois | WPRIM | ID: wpr-508112
ABSTRACT

Objective:

To explore the clinical efficacy and the effects on serum inflammatory factors of carbocisteine and budes-onide in the treatment of asthma.

Methods:

Totally 186 asthma patients were randomly divided into the observation group (93 cases) and the control group (93 cases). The control group received budesonide combined with the conventional treatment, the observation group was treated with carbocisteine and budesonide, and one week was a treatment course. The efficacy was observed. The airway re-sponsiveness and cough condition was respectively assessed by early respiratory resistance ( Rrsc) and Leicester cough questionnaire ( LCQ) . The improvement of day and night symptoms was observed, and the serum levels of inflammatory factors and the safety were also evaluated.

Results:

LCQ score of the observation group after the treatment was significantly higher than that of the control group, Rrsc score for day and night symptoms and serum IL-8, TNF-αand IgE levels were significantly lower than those in the control group, and the differences were statistically significant (P0. 05). The difference in the in-cidence of ADR between the groups was not statistically significant (P>0. 05).

Conclusion:

Carbocisteine and budesonide in the treatment of asthma can significantly improve asthma symptoms and reduce cough and inflammatory cytokines with promising safety.

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) langue: Chinois Texte intégral: China Pharmacist Année: 2017 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) langue: Chinois Texte intégral: China Pharmacist Année: 2017 Type: Article